

Glenmark to commercialise Ryaltris in Australia, NZ

06 July 2018 | News

Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.



Glenmark Pharma's subsidiary Glenmark Specialty has entered into an exclusive licensing agreement with Australia's Seqirus to commercialise its nasal spray Ryaltris in Australia and New Zealand.

Ryaltris is indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialisation of the product in Australia and New Zealand.

Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.

In May 2018, Glenmark filed a New Drug Application (NDA) for Ryaltris with the US Food and Drug Administration (USFDA).

The company plans to commercialise Ryaltris in several key markets globally.